CTA
ABBV icon

Chesley Taft & Associates’s AbbVie ABBV Stock Holding History

Chesley Taft & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.01M Sell
19,924
-187
-0.9% -$40.2K 0.2% 92
2026
Q1 		$4.37M Sell
20,111
-2,640
-12% -$586K 0.18% 98
2025
Q4 		$5.2M Buy
22,751
+3,501
+18% +$798K 0.21% 90
2025
Q3 		$4.46M Sell
19,250
-1,832
-9% -$373K 0.19% 100
2025
Q2 		$3.91M Buy
21,082
+234
+1% +$43.5K 0.17% 110
2025
Q1 		$4.37M Buy
20,848
+575
+3% +$112K 0.21% 95
2024
Q4 		$3.6M Buy
20,273
+262
+1% +$48.2K 0.17% 103
2024
Q3 		$3.95M Sell
20,011
-432
-2% -$80.6K 0.19% 95
2024
Q2 		$3.51M Sell
20,443
-495
-2% -$82K 0.18% 98
2024
Q1 		$3.81M Buy
20,938
+220
+1% +$37.9K 0.2% 96
2023
Q4 		$3.21M Sell
20,718
-160
-0.8% -$23.3K 0.18% 101
2023
Q3 		$3.11M Sell
20,878
-1,198
-5% -$176K 0.2% 100
2023
Q2 		$2.97M Sell
22,076
-1,301
-6% -$191K 0.18% 109
2023
Q1 		$3.73M Buy
23,377
+959
+4% +$147K 0.24% 90
2022
Q4 		$3.62M Buy
22,418
+561
+3% +$86K 0.25% 91
2022
Q3 		$2.93M Sell
21,857
-275
-1% -$39.5K 0.22% 102
2022
Q2 		$3.39M Buy
22,132
+290
+1% +$44.3K 0.23% 98
2022
Q1 		$3.65M Sell
21,842
-146
-0.7% -$21.2K 0.21% 99
2021
Q4 		$2.98M Sell
21,988
-590
-3% -$69.7K 0.15% 119
2021
Q3 		$2.44M Sell
22,578
-10
-0% -$1.14K 0.14% 126
2021
Q2 		$2.54M Buy
22,588
+410
+2% +$46.2K 0.15% 122
2021
Q1 		$2.35M Buy
22,178
+408
+2% +$43.6K 0.14% 121
2020
Q4 		$2.33M Buy
21,770
+270
+1% +$25.9K 0.15% 115
2020
Q3 		$1.88M Buy
21,500
+440
+2% +$41.4K 0.13% 119
2020
Q2 		$2.07M Buy
21,060
+8,101
+63% +$713K 0.16% 109
2020
Q1 		$987K Sell
12,959
-1,837
-12% -$156K 0.09% 146
2019
Q4 		$1.31M Buy
14,796
+376
+3% +$31.2K 0.09% 144
2019
Q3 		$1.09M Sell
14,420
-380
-3% -$26.1K 0.08% 153
2019
Q2 		$1.08M Sell
14,800
-1,695
-10% -$133K 0.08% 151
2019
Q1 		$1.33M Sell
16,495
-1,875
-10% -$153K 0.11% 136
2018
Q4 		$1.69M Sell
18,370
-41,770
-69% -$3.67M 0.16% 112
2018
Q3 		$5.69M Sell
60,140
-34,475
-36% -$3.27M 0.45% 63
2018
Q2 		$8.77M Sell
94,615
-530
-0.6% -$51.8K 0.75% 44
2018
Q1 		$9.01M Sell
95,145
-1,600
-2% -$176K 0.8% 43
2017
Q4 		$9.36M Sell
96,745
-12,747
-12% -$1.2M 0.79% 42
2017
Q3 		$9.73M Sell
109,492
-648
-0.6% -$49.3K 0.84% 38
2017
Q2 		$7.99M Sell
110,140
-625
-0.6% -$42K 0.72% 44
2017
Q1 		$7.22M Buy
110,765
+2,845
+3% +$179K 0.68% 48
2016
Q4 		$6.76M Buy
107,920
+11,021
+11% +$673K 0.67% 51
2016
Q3 		$6.11M Sell
96,899
-690
-0.7% -$44.7K 0.62% 50
2016
Q2 		$6.04M Hold
97,589
– – 0.62% 49
2016
Q1 		$5.57M Sell
97,589
-2,895
-3% -$161K 0.59% 53
2015
Q4 		$5.95M Sell
100,484
-4,137
-4% -$238K 0.63% 52
2015
Q3 		$5.69M Buy
104,621
+1,867
+2% +$122K 0.62% 54
2015
Q2 		$6.9M Sell
102,754
-375
-0.4% -$24.5K 0.7% 48
2015
Q1 		$6.04M Buy
103,129
+200
+0.2% +$12.1K 0.62% 55
2014
Q4 		$6.74M Sell
102,929
-150
-0.1% -$9.46K 0.68% 50
2014
Q3 		$5.95M Sell
103,079
-787
-0.8% -$43.7K 0.62% 56
2014
Q2 		$5.86M Sell
103,866
-550
-0.5% -$28.9K 0.61% 61
2014
Q1 		$5.37M Buy
104,416
+1,292
+1% +$65.3K 0.58% 64
2013
Q4 		$5.45M Buy
103,124
+7,404
+8% +$364K 0.54% 68
2013
Q3 		$4.28M Buy
95,720
+233
+0.2% +$10.3K 0.47% 72
2013
Q2 		$3.95M Buy
+95,487
New +$4.18M 0.46% 72

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Chesley Taft & Associates's ABBV Position: Q2 2026 in Review

Chesley Taft & Associates reduced its AbbVie (ABBV) stake by 0.93% in Q2 2026, selling an estimated $40.2K and leaving 19,924 shares worth $5.01M. The position accounts for 0.2% of the portfolio, ranked #92.

Chesley Taft & Associates first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.73M in Q3 2017. 1,156 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Chesley Taft & Associates held 19,924 shares of AbbVie worth $5.01M as of Q2 2026.
  • Chesley Taft & Associates sold 187 AbbVie shares in Q2 2026, an estimated $40.2K.
  • AbbVie made up 0.2% of Chesley Taft & Associates's portfolio in Q2 2026, its #92 holding.
  • Chesley Taft & Associates first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Chesley Taft & Associates's AbbVie position peaked at $9.73M in Q3 2017.
  • 1,156 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Chesley Taft & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.